Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
Crawford
J
J
Department of Medicine, Duke University Medical Center, Durham, USA.
Caserta
C
C
Roila
F
F
D005060:Europe / Q000453:epidemiology; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D007377:Interleukin-3 / Q000627:therapeutic use*; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D011092:Polyethylene Glycols; D011994:Recombinant Proteins
D016298:Hematopoietic Cell Growth Factors; D007377:Interleukin-3; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim